Medpage Today just ran an article about anti-cancer related advances from ASCO. I always find it interesting to take a look at what more general cancer related sites consider noteworthy about the world of multiple myeloma. This extensive article only featured one myeloma related study from ASCO:
CHICAGO — A chemical cousin to the infamous drug thalidomide sharply cut recurrence of multiple myeloma in a prospective randomized trial, a researcher said.
Maintenance therapy with lenalidomide (Revlimid) after autologous stem-cell transplant reduced the risk of recurrence by 54% after three years, compared with placebo, according to Michel Attal, MD, of Purpan Hospital in Toulouse, France.
Here is a link to the article about how Revlimid maintenance therapy showed impressive results in this three year French study.
Feel good and keep smiling! Pat